FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 1). | 購回股份(或其他證券)但沒有註銷 | 379,300 | 0.02 % | RMB | 52.75 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月18日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 379,300股A股股份。 | | | | | | | 變動日期 2025年4月18日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | | | | | | | | 374,000 | 0.01 % | RMB | 53.5 | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月21日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 374,000股A股股份。 | | | | | | | 變動日期 2025年 ...

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (603259) [2] Core Insights - WuXi AppTec reported a significant revenue increase of 21.0% year-on-year, reaching 9.65 billion yuan in Q1 2025, with a notable 89.1% growth in net profit attributed to one-time investment gains [5][8] - The company has a strong order backlog of 52.33 billion yuan, reflecting a 47.1% year-on-year increase, with TIDES orders growing by 105.5% [8] - The company plans to distribute a special dividend of 1 billion yuan in addition to maintaining a 30% annual cash dividend ratio, alongside a share buyback of 1 billion yuan [8] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 42.77 billion yuan, with a year-on-year growth rate of 9.0% [7] - The forecasted net profit for 2025 is 11.27 billion yuan, representing a 19.3% increase compared to the previous year [7] - The report anticipates a continued double-digit growth trajectory for the company's core business, with overall revenue expected to reach between 41.5 billion and 43 billion yuan [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） (1) 2024年股東週年大會、2025年第一次A股類別股東大會和 2025年第一次H股類別股東大會投票結果； (2) 派付末期股息及特別股息； 及 (3) 修訂公司章程 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月26日刊 發的通函（「通函」）；及(ii)於2025年3月26日刊發的2024年股東週年大會（「2024年 股東週年大會」）通告（「2024年股東週年大會通告」）及於2025年3月26日刊發的 本公司2025年第一次H股類別股東大會（「2025年第一次H股類別股東大會」）通告 （連同2024年股東週年大會通告，統稱為「該等通告」）。除非文義另有所指，否 則本公告已界定的詞語在通函及該等通告中具有相同涵義。 本公司董事（「 ...

Investment Rating - The investment rating for WuXi AppTec (603259) is "Buy" [5] Core Views - The company's Q1 2025 performance exceeded market expectations, with a revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit attributable to shareholders of 3.672 billion yuan, up 89.06% year-on-year [1][2] - The TIDES business significantly contributed to the core performance elasticity, with a revenue of 2.24 billion yuan, representing a remarkable growth of 187.6% year-on-year [2] - The company has a strong order backlog of 52.33 billion yuan, a year-on-year increase of 47.1%, indicating a continued high growth trend [2] Summary by Sections Financial Performance - For Q1 2025, the company achieved a revenue of 9.655 billion yuan, a 21.0% increase year-on-year, with adjusted profit reaching 2.68 billion yuan, up 40% [2] - The chemical business generated 7.39 billion yuan in revenue, a 32.9% increase year-on-year, while the small molecule CDMO business saw a revenue of 3.85 billion yuan, growing 13.8% [2] - The testing and biology segments reported revenues of 1.29 billion yuan and 610 million yuan, showing a decline of 4% and an increase of 8.2% respectively [2] Future Outlook - The company expects a revenue growth guidance of 10% to 15% for its continuing operations in 2025, supported by rapid order growth and ongoing cost reduction efforts [2] - The adjusted revenue forecasts for 2025-2027 are 42.724 billion yuan, 49.093 billion yuan, and 56.747 billion yuan respectively, with EPS estimates of 4.17 yuan, 4.94 yuan, and 5.85 yuan [3][8] Valuation Metrics - The PE ratios for 2025, 2026, and 2027 are projected to be 15, 12, and 10 respectively, based on the closing price of 60.45 yuan per share on April 29, 2025 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 董事長 李革博士 香港，2025年4月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 FANGDA PARTNERS http://www.fangdalaw.com 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 中国北京市朝阳区光华路一号 电子邮件 E-mail: email@fangdalaw.com 北 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 2025 年 4 月 29 日，无锡药明康德新药开发股份有限公司（以下简称"本公 司"或"公司"）召开 2024 年年度股东大会、2025 年第一次 A 股类别股东会议 及 2025 年第一次 H 股类别股东会议，审议通过了《关于给予董事会回购公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规和/或 规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过该议 案经股东大会、A 股及 H 股类别股 ...

茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年4月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-032 无锡药明康德新药开发股份有限公司 2024年年度股东大会、2025 年第一次 A 股类别股东会 议及 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 第 2 頁 共 8 頁 v 1.3.0 | 7). | 購回股份(或其他證券)但沒有註銷 | 347,756 | 0.01 % | RMB | 57.53 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月28日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 347,756股A股股份。 | | | | | | | 變動日期 2025年4月28日 | | | | | | 8). | 購回股份(或其他證券)但沒有註銷 | 329,400 | 0.01 % | RMB | 60.74 | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月29日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 329,400股A股股份。 | | | | | | ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 22,008.11 points, up 0.16% or 36.15 points, with a total turnover of HKD 1,776.58 million [1] - The Hang Seng Tech Index rose by 0.62% to 5,019.73 points, while the Hang Seng China Enterprises Index fell by 0.15% to 8,067.94 points [1] Blue Chip Performance - WuXi AppTec (02359) saw a significant increase of 4.21%, closing at HKD 60.65, contributing 1.39 points to the Hang Seng Index. The company reported a revenue of approximately HKD 9.655 billion for Q1, a year-on-year increase of 20.96%, and a net profit of approximately HKD 3.672 billion, up 89.06% [2] - Other notable blue chips included Alibaba Health (00241) up 7.16%, Geely Automobile (00175) up 4.18%, while Techtronic Industries (00669) and CNOOC (00883) saw declines of 2.35% and 1.53% respectively [2] Sector Highlights - Large tech stocks mostly rose, with Meituan up 2.88% and JD.com up 1.9%, while Tencent fell over 1% [3] - Consumer stocks showed strong performance, with MaoGeping up nearly 9% and Nayuki Tea rising over 8%. The report indicated that new consumption trends are driving brand upgrades and market growth [3] - The tea beverage brand HuShang Ayi began its IPO process, with a subscription amount reaching HKD 10.298 billion and a subscription multiple of 377.51 times [4] Automotive Sector - Automotive stocks generally rose, with Li Auto (09863) up 8.08% and NIO (09866) up 4.91%. The U.S. President announced measures to reduce the impact of auto tariffs, which may benefit the sector [5][4] - The report noted that the penetration rate of new energy vehicles reached 53.3%, indicating strong growth in the automotive market [5] Biopharmaceutical Sector - Biopharmaceutical stocks performed well, with Yunnan Baiyao (01952) up 9.75% and Lepu Biopharma (02157) up 8.49%. The upcoming AACR and ASCO meetings are expected to catalyze further growth in the innovative drug sector [6] Notable Stock Movements - Yao Cai Securities (01428) surged by 31.53% following an announcement of a significant acquisition by Ant Group [7] - Horizon Robotics (09660) rose by 13.71%, with projections indicating substantial revenue growth driven by advancements in autonomous driving technology [8] - HSBC Holdings (00005) saw a mild increase of 3.03%, with plans for a share buyback of up to USD 3 billion [9] - Qingdao Beer (00168) fell by 4.07% despite reporting a revenue increase of 2.91% for Q1 [10]

Financial Data and Key Metrics Changes - In Q1 2025, revenue from continuing operations grew 23.1% year over year to RMB 9.39 billion, while total revenue reached RMB 9.65 billion, representing a 21% year over year growth [9] - Adjusted non-IFRS net profit increased 40% year over year to RMB 2.68 billion, with a record backlog for continuing operations of RMB 52.33 billion, growing 47.1% year over year [9][10] - Adjusted IFRS gross profit margin reached 41.9%, with net profit attributable to owners increasing by 89.1% year over year [25][26] Business Line Data and Key Metrics Changes - Wuxi Chemistry's CRDMO business revenue grew 32.9% year over year to RMB 7.39 billion, with adjusted non-IFRS gross profit margin improving by 4.2 percentage points to 47.5% [11][12] - Small molecule DNM business revenue grew 13.8% year over year to RMB 3.85 billion, with both Changzhou and Taishin API manufacturing sites passing FDA inspections [13] - Tides business achieved revenue of RMB 2.24 billion in Q1, representing a strong growth of 187.6% year over year [14] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 28.4% year over year, while revenue from Europe grew 26.2% year over year; however, China showed a slight decline [10] - Revenue from Wuxi Testing decreased by 4% year over year to RMB 1.29 billion, with lab testing revenue down 4.9% due to market pricing impacts [18][19] Company Strategy and Development Direction - The company will continue to focus on the CRDMO business model with an emphasis on operational efficiency and exceptional services [29] - Full year guidance remains at 10% to 15% revenue growth, targeting total revenue of RMB 41.5 billion to RMB 43 billion [30] - The company plans to accelerate global D and M capacity expansion, with CapEx expected to reach RMB 7 billion to RMB 8 billion [30] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining full year guidance despite external uncertainties, emphasizing the resilience of the management team [29][30] - The company is closely monitoring changes in the global macro environment and will communicate any changes in guidance promptly [30][31] Other Important Information - The Board of Directors proposed maintaining a 30% annual cash dividend payout ratio, totaling approximately RMB 2.8 billion, along with a one-time special cash dividend of RMB 1 billion [31] - The company announced plans to repurchase and cancel RMB 1 billion worth of A shares in 2025 [32] Q&A Session Summary Question: What are the key drivers behind the robust growth in Tides? - Management indicated that the strong growth in Tides was due to both capacity ramp-up and a relatively low base from the previous year [37] Question: How does the company view the impact of tariffs on business segments? - Management acknowledged that tariffs are a systemic challenge affecting global operations, but emphasized efforts to optimize and diversify the supply chain to mitigate impacts [44][46] Question: What is the projected CapEx for 2025 and its allocation? - The projected CapEx is RMB 7 billion to RMB 8 billion, primarily focused on expanding D and M manufacturing capacity in various geographies [50][54] Question: How does the company plan to improve profit margins? - Management stated that continuous focus on operational efficiency and process development excellence will help improve margins, despite potential pressures from new capacity ramp-up [78][81]